Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03821935 |
|---|---|
| Brief Title: | Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors |
| First Submitted : | January 28, 2019 |
| First Submitted that Met QC Criteria : | January 28, 2019 |
| First Posted : | January 30, 2019 |
| Last Update Submitted that Met QC Criteria : | April 29, 2024 |
| Last Update Posted : | April 30, 2024 |